CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310 ®, its ...

NEW ORLEANS, LA—An investigational CRISPR-Cas9 gene-editing therapy that targets angiopoietin-like protein 3 (ANGPTL3), which has a role in regulating lipid metabolism, appears to safely lower levels ...

Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the ...

A single intravenous infusion of an experimental CRISPR-Cas9 therapy cut LDL cholesterol by 52.5% in patients who received ...

In CRISPR gene editing, guide RNA (gRNA) directs the Cas9 complex to its target. Impurities introduced during gRNA synthesis ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

CRISPR-Cas9 has transformed the life sciences by giving researchers a seemingly simple tool for cutting DNA at chosen ...

CRISPR-Cas9 removed an extra chromosome 21 from some Down syndrome cells in the lab. Learn what the 30.6% result means and ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Most of any gains (or lack thereof) from here will be driven by just three factors.

A single dose of an experimental CRISPR therapy cut LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. The reductions were still present one year ...